GLP-1 Therapy Is More Than a Prescription

GLP-1–based medications have changed the conversation around obesity, diabetes and cardiometabolic health. For the right patient, they can be powerful tools. But a powerful tool still requires judgment, preparation and follow-through. Too often, I have watched these therapies be handed out almost like candy: a prescription, a generic set of instructions and a follow-up scheduled months later. That is not the standard of care I believe patients deserve.

A medication should never replace a thoughtful clinical relationship. Before treatment begins, I want to understand the patient’s health history, current symptoms, nutritional intake, activity level, sleep, medications, laboratory results and cardiovascular risk. I also want to understand what success means to that individual. The goal may include weight reduction, but it should also include preserving strength, improving metabolic health, lowering risk and creating habits that remain useful long after the first dose.

My perspective is personal

I have lived with type 1 diabetes since I was nine years old. I understand metabolic disease not only from textbooks, operating rooms and clinical practice, but from the daily reality of glucose management. I know that small decisions accumulate. Food, movement, stress, sleep, medication timing and access to knowledgeable support can all influence how a person feels and how safely a treatment plan works.

That experience shapes the way I practice. I do not believe in handing a patient a prescription and disappearing for eight or twelve weeks. I believe in careful education, appropriate monitoring and availability when questions arise. Side effects, changes in appetite, hydration problems or uncertainty about nutrition should be addressed early—not after they have already disrupted the patient’s progress.

Weight loss is not the only outcome

The number on the scale matters, but it does not tell the whole story. Significant weight loss can include loss of lean tissue as well as fat. In an exploratory body-composition analysis from the STEP 1 semaglutide trial, total fat mass decreased substantially, but total lean body mass also decreased. That is one reason I emphasize adequate nutrition, protein intake and resistance exercise rather than treating appetite suppression as the entire plan.

The objective is not simply to become lighter. It is to become healthier, more capable and more metabolically resilient. A patient who loses weight while becoming weak, undernourished or disengaged from exercise has not received a complete strategy. Treatment should protect function and support a sustainable life.

Exercise must remain part of the prescription

Exercise supports cardiovascular fitness, insulin sensitivity, strength, mobility and long-term weight maintenance. A GLP-1 medication may make a calorie deficit easier to achieve, but it does not replace the physiologic value of movement. I work with patients to assess what they can safely do and to establish a realistic plan that includes aerobic activity and resistance training when appropriate.

This is not about perfection. It is about building consistency and adjusting the plan to the patient’s medical history, schedule, current fitness and limitations. A sustainable regimen is more valuable than an aggressive program that lasts two weeks.

The cardiovascular opportunity matters

These therapies deserve attention for reasons beyond weight. In the large SELECT cardiovascular outcomes trial, semaglutide reduced the rate of major adverse cardiovascular events among adults with established cardiovascular disease and overweight or obesity but without diabetes. The event occurred in 6.5% of participants receiving semaglutide and 8.0% receiving placebo—a 20% relative risk reduction.

That finding does not mean every patient should receive the medication or that medication replaces a full cardiovascular evaluation. It means the clinical conversation should consider the entire risk profile: family history, blood pressure, lipids, glucose, symptoms, physical findings, activity, tobacco exposure and other relevant factors. Used thoughtfully, treatment can become one element of a broader risk-reduction strategy.

Sleep apnea belongs in the conversation

Obstructive sleep apnea is closely connected to cardiometabolic health. It can affect daytime function, blood pressure, glucose regulation and cardiovascular risk. In the SURMOUNT-OSA trials, tirzepatide produced substantially greater reductions in apnea-hypopnea index than placebo in adults with obesity and moderate-to-severe obstructive sleep apnea.

Those results reinforce the value of looking beyond weight alone. When a patient reports loud snoring, witnessed pauses in breathing, morning headaches, daytime sleepiness or poor-quality sleep, those symptoms deserve attention. Medication may contribute to improvement in an appropriate patient, but evaluation and coordination with sleep specialists remain important.

Follow-up is not optional

The difference between merely dispensing a drug and managing therapy is follow-up. Patients need a way to ask questions, report side effects and discuss changes before a small concern becomes a larger problem. Dosing should be individualized rather than increased automatically. Some patients require slower titration, additional nutritional support or a different plan altogether.

Availability is central to the Pulse model. I want patients to feel that a real clinician knows their story and remains within reach. That direct connection cannot be replaced by an advertisement, an automated questionnaire or a package arriving at the door. Technology can improve access, but it should support human care—not remove it.

Medication should support a better life

My approach to GLP-1 therapy is holistic because metabolic health is holistic. It includes appropriate patient selection, a thorough history and physical examination, individualized dosing, nutrition, hydration, exercise, muscle preservation, glucose awareness, cardiovascular risk and continuity with the patient’s other clinicians. When appropriate and authorized by the patient, visit findings can be shared with a primary care clinician or specialist to maintain continuity of care.

GLP-1 therapy can be transformative, but the medication is not the entire treatment. The standard should be knowledgeable evaluation, careful monitoring and a provider who is present throughout the process. Patients deserve more than access to a prescription. They deserve care.

This article is for educational purposes and does not constitute individual medical advice. GLP-1–based medications are prescription therapies with potential risks, contraindications and side effects. Treatment decisions should be made after an individualized evaluation by a qualified healthcare professional.